Evaluation of top-selling biotechnological medicine from 2003 to 2016 in Turkey Türkiye’de 2003-2016 Yılları Arasında En Çok Satılan Biyoteknolojik İlaçların Değerlendirilmesi


Creative Commons License

Vural E. H., Yılmaz E. Ş., Bektemür G., Vural İ. M., Bayar B., Gürsöz H.

Haseki Tip Bulteni, vol.57, no.2, pp.108-113, 2019 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 57 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.4274/haseki.galenos.2018.4566
  • Journal Name: Haseki Tip Bulteni
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.108-113
  • Keywords: Pharmaceutical market in Turkey, medicines with high sales, biopharmaceutical medicines, policy interventions
  • Lokman Hekim University Affiliated: No

Abstract

© 2019 by The Medical Bulletin of İstanbul Haseki Training and Research Hospital.Aim: The top 100 medicines having the highest annual average sales between the years 2006 and 2015, had exceeded one-fourth of the total pharmaceutical market’s value in these years. We aimed to study the status of biotechnological medicines among these medicines and evaluate the effects of policy interventions on their sales. Methods: Sales of all medicines on an annual average value basis were calculated. The top 100 medicines with the highest annual average sales were included in the study. Time series analysis has been used for prospective estimations. Results: Up to 2007 biotechnological medicines had not been in the top ten medicines; it increased dramatically after 2007 and in 2016, the sales of biotechnological medicines reached to 82% in top 10 sales in Turkey. On the other hand the number of biotechnological medicines among the top 100 medicines was 4 in 2003; it reached to 27 in 2016. However the number of biotechnological medicines in the top 10 medicines was 1 in 2003 and it reached to 8 in 2016. Conclusion: The shares of biotechnological medicines in both the total pharmaceutical market and in the group of medicines with high sales are increasing every year. New policies should be developed to ensure the stability of the reimbursement system.